🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 75 of 173

  1. US 9814422

    Compositions for solubilizing cells and/or tissue

    Expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9814755

    Methods for the treatment of depression and anxiety

    Expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9814729

    Nerve agent antidotes

    Expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9816075

    Compounds with modifying activity enhanced under hypoxic conditions

    Expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9815890

    Antibodies to the C3d fragment of complement component 3

    Expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9816066

    Method for delivery of small molecules and proteins across the cell wall of algae using molecular transporters

    Expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9815870

    Monomeric and bright infrared fluorescent proteins

    Expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9814689

    Enterically coated cysteamine, cystamine and derivatives thereof

    Expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9808460

    Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders

    Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9809588

    GLS1 inhibitors for treating disease

    Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9808532

    Peptides whose uptake in cells is controllable

    Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9808486

    Administration of kynurenine depleting enzymes for tumor therapy

    Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9808475

    Bovine milk oligosaccharides

    Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9808448

    Pharmaceutical compounds and use of same in cancer and tauopathies

    Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9808428

    Compositions and methods for the delivery of therapeutics

    Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9808543

    Iron garnet nanoparticles for cancer radiotherapy and chemotherapy

    Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9808505

    Suppression of malignant mesothelioma by overexpression or stimulation of endothelial protein C receptors (EPCR)

    Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9801962

    Radioactive nanoparticles and methods of making and using the same

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9801911

    Expansion of alloantigen-reactive regulatory T cells

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9801848

    Prevention of rosacea inflammation

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9801863

    Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9803187

    Baulamycins, compositions and methods of use thereof

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9803021

    CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9801954

    Lipid substitution on aminoglycoside based polymers: plasmid delivery, anticancer drug delivery and transgene expression

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9801944

    Lipocationic polymers and uses thereof

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9801842

    Nanoemulsion therapeutic compositions and methods of using the same

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9801922

    Compositions and methods of treating cancer

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9801884

    Nucleotide analogs

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9796961

    Conditionally immortalized long-term stem cells and methods of making and using such cells

    Expires Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9795673

    Treating macular degeneration using antibodies to aminophospholipids

    Expires Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9795578

    Enterically coated cysteamine, cystamine and derivatives thereof

    Expires Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9796671

    Aurora kinase inhibitors

    Expires Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9796759

    Ang-(1-7) derivative oligopeptides and methods for using and producing the same

    Expires Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9789096

    Methods and compositions for selective and targeted cancer therapy

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9789224

    Compositions and methods for cardiac therapy

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9790274

    Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9790506

    Diagnostic and screening methods for atopic dermatitis

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9790495

    Antisense antibacterial compounds and methods

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9790218

    Small molecule activators of calcium-activated chloride channels and methods of use

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9790233

    Compositions and methods of modulating 15-PGDH activity

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9790272

    Stem cell factor inhibitor

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9790180

    Piperidine derivatives as HDAC1/2 inhibitors

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9789209

    Activatable membrane-interacting peptides and methods of use

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9789205

    Compositions and methods for gene therapy

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9789180

    D-amino acid derivative-modified peptidoglycan and methods of use thereof

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9789176

    Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9789136

    Multipotent adult stem cells and methods for isolation

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9789144

    Inhibition of hypoxia-inducible factor activity with Carica papaya extracts

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.